Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

BCR-ABL1 p190 in CML: A Minor Breakpoint with a Major Impact

Shady Adnan Awad, MD, Helena Hohtari, MD, Komal Kumar Javarappa, PhD, Tania Brandstoetter, Daehong Kim, Swapnil Potdar, MSc, Caroline A Heckman, PhD, Soili Kytölä, PhD, Kimmo Porkka, Eszter Doma, PhD, Veronika Sexl, MD PhD, Matti Kankainen, PhD, Satu Mustjoki, MD PhD

Blood (2019) 134 (Supplement_1): 190.

https://doi.org/10.1182/blood-2019-126584

Published: 2019

Journal Articles

The Role of the BMP Pathway in Sustaining CML Stem Cells in the Bone Marrow Niche

Caroline Busch, BSc, MSc, Chloe Gulliver, BSc, MSc, Theresa Mulholland, BSc, Michele Zagnoni, BSc, MSc, PhD, Catherine C. Berry, BSc,PhD, Helen Wheadon, BSc, PhD

Blood (2019) 134 (Supplement_1): 3732.

https://doi.org/10.1182/blood-2019-123967

Published: 2019

Journal Articles

High-Throughput Functional Ex-Vivo Drug Testing and Multi-Omics Profiling in Patients with Acute Myeloid Leukemia

Tom Erkers, PhD, Brinton Seashore-Ludlow, Nona Struyf, Francesco Marabita, Tojo James, Disha Malani, Mattias Vesterlund, Matthias Stalhl, Yudi Pawitan, Sören Lehmann, MD PhD, Päivi Östling, Janne Lehtiö, Olli Kallioniemi

Blood (2019) 134 (Supplement_1): 4641.

https://doi.org/10.1182/blood-2019-124332

Published: 2019

Journal Articles

The Influence of the Bone Marrow Niche on Drug Response Phenotypes of Blood Cancers

Sophie Rabe, MSc, Eva Schitter, Tobias Roider, Peter-Martin Bruch, Carolin Kolb, Marta Stolarczyk, Jennifer Hüllein, Junyan Lu, Christof von Kalle, Christoph Lutz, Peter Dreger, Carsten Mueller-Tidow, Thorsten Zenz, MD, Wolfgang Huber, Sascha Dietrich, MD

Blood (2018) 132 (Supplement 1): 262.

https://doi.org/10.1182/blood-2018-99-116053

Published: 2018

Journal Articles

Gene-Drug Interactions in AML Patients Identified By RNA Sequencing and Comprehensive Ex Vivo Drug Sensitivity and Resistance Testing

Ashwini Kumar, MRes, Dishaben Rameshbhai Malani, MSc, Bhagwan Yadav, PhD, Matti Kankainen, PhD, Swapnil Potdar, MSc, Mika Kontro, MD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD, Simon Anders, PhD, Caroline A Heckman, PhD

Blood (2017) 130 (Supplement 1): 1398.

https://doi.org/10.1182/blood.V130.Suppl_1.1398.1398

Published: 2017

Journal Articles

Sequential Cellular Niche Plays a Crucial Role in the Generation of Enucleated Erythrocytes from Human Pluripotent Stem Cells

Jun Shen, Ziceng Feng, Cuicui Lyu, Dixie Hoyle, Guangzhen Ji, Wei Wen, Jing Xu, Lu Zhang, Jianping Zhang, Xiaobing Zhang, Tao Cheng, MD, Zack Wang, PhD

Blood (2017) 130 (Supplement 1): 1159.

https://doi.org/10.1182/blood.V130.Suppl_1.1159.1159

Published: 2017

Journal Articles

Single-Cell Drug Profiling Reveals Maturation Stage-Dependent Drug Responses in AML

Heikki Kuusanmäki, MSc, Maija Leppä, BSc, Mika Kontro, MD, Olli Dufva, BSc, Debashish Deb, MSc, Bhagwan Yadav, PhD, Satu Mustjoki, MDPhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2017) 130 (Supplement 1): 3821.

https://doi.org/10.1182/blood.V130.Suppl_1.3821.3821

Published: 2017

Journal Articles

Integration of Functional Ex Vivo Drug Testing and Molecular Profiling Reveals Novel Vulnerabilities in CMML

Tea Pemovska, PhD, Gregory Ian Vladimer, PhD, Vitaly Sedlyarov, PhD, Emir Hadzijusufovic, DVM, Karoline Veronika Gleixner, MD, Alexandra Keller, MSc, Berend Snijder, PhD, Nikolaus Krall, PhD, Oscar Lopez de la Fuente, BSc, Mathias A Schneeweiss, MD, Wolfgang R. Sperr, MD, Paul Knöbl, MD PhD, Klaus Geissler, MD, Philipp Bernhard Staber, MD PhD, Ulrich Jaeger, MD, Peter Valent, MD, Giulio Superti Furga, PhD

Blood (2017) 130 (Supplement 1): 4227.

https://doi.org/10.1182/blood.V130.Suppl_1.4227.4227

Published: 2017

Journal Articles

Identification of Optimized Compound Combinations for the Treatment of NUP98-NSD1+ AML

Jarno Kivioja, MSc, Angeliki Thanasopoulou, PhD, Mika Kontro, MD, Bhagwan Yadav, MSc, Muntasir Mamun Majumder, MSc, Heikki Kuusanmäki, MSc, Alun Parsons, MSc, Kimmo Porkka, MD PhD, Juerg Schwaller, MD, Caroline A Heckman, PhD

Blood (2016) 128 (22): 4711.

https://doi.org/10.1182/blood.V128.22.4711.4711

Published: 2016

Journal Articles

Ex-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform

Laura Rocchi, PhD, Andrea Faenza, PhD, Laura Rambelli, Viviana Guadagnuolo, PhD, Giovanni Marconi, MD, Giorgia Simonetti, PhD, Cristina Papayannidis, MD PhD, Antonella Padella, Nicola Pecorari, Luca Giulianelli, Dario Biscarini, Giovanni Martinelli, MD PhD, Roberto Guerrieri, PhD, Massimo Bocchi, PhD

Blood (2016) 128 (22): 1675.

https://doi.org/10.1182/blood.V128.22.1675.1675

Published: 2016

Journal Articles

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Emma I Andersson, MSc, Shady Adnan, MD MSc, Leopold Sellner, MD, Dorine Bellanger, Alexandra Schrader, Giuliano Crispatzu, Henan Zhang, MD, Carlos C Mateos, PhD, Edgar Faber, MD PhD, Steffen Koschmieder, MD, Tim H. Brummendorf, MD PhD, Krister Wennerberg, PhD, Wei Ding, MD PhD, Marc-Henri Stern, MD PhD, Marco Herling, MD, Simon Anders, PhD, Wolfgang Huber, PhD, Thorsten Zenz, MD, Satu Mustjoki, MD, PhD

Blood (2015) 126 (23): 315.

https://doi.org/10.1182/blood.V126.23.315.315

Published: 2015

Journal Articles

Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Emma I Andersson, MSc, Leopold Sellner, MD, Malgorzata Oles, Tea Pemovska, MSc, Paavo Pietarinen, MSc, Anneli Lauhio, MD, Katarzyna Tomska, Carlos Cuesta-Mateos, MD PhD, Edgar Faber, Tim H. Brummendorf, MD PhD, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD, Wolfgang Huber, PhD, Krister Wennerberg, PhD, Thorsten Zenz, MD, Satu Mustjoki, MDPhD

Blood (2014) 124 (21): 917.

https://doi.org/10.1182/blood.V124.21.917.917

Published: 2014

Journal Articles

Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma

Muntasir Mamun Majumder, MSc,BPharm, Raija Silvennoinen, MD, Pekka Antilla, David Tamborero, Samuli Eldfors, MSc, Riikka Karjalainen, MSc, Heikki Kuusanmäki, MSc, Juha Lievonen, MD, Alun Parsons, MSc, Minna Suvela, Marjanna Säily, Bhagwan Yadav, MSc, Krister Wennerberg, PhD, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 2046.

https://doi.org/10.1182/blood.V124.21.2046.2046

Published: 2014

Journal Articles

Development of in Vivo Models of Paediatric Burkitt Lymphoma Allowing Therapeutic Target Analysis and Drug Testing

Natalie Bell, PhD, Helen J Blair, PhD, Josef Vormoor, MD FRCPCH, Chris Bacon, MBChB, PhD, Vikki Rand, PhD, Olaf Heidenreich, PhD, Simon Bomken, PhD MBBS

Blood (2014) 124 (21): 5501.

https://doi.org/10.1182/blood.V124.21.5501.5501

Published: 2014

Journal Articles

Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing

Riikka Karjalainen, MSc, Tea Pemovska, MSc, Muntasir Mamun Majumder, MSc, David Tamborero, PhD, Bhagwan Yadav, MSc, Mika Kontro, MD, Bjørn Gjertsen, MD PhD, Alun Parsons, MSc, Minna Suvela, BSc, Tero Aittokallio, PhD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD, Krister Wennerberg, PhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 3505.

https://doi.org/10.1182/blood.V124.21.3505.3505

Published: 2014

Journal Articles

Stromal Cell Supported High-Throughput Drug Testing Of Primary Leukemia Cells For Comprehensive Assessment Of Sensitivity To Novel Therapies

Riikka Karjalainen, MSc, Tea Pemovska, MSc, Bhagwan Yadav, MSc, Muntasir Mamun Majumder, MSc, Mika Kontro, MD, Kimmo Porkka, MD, PhD, Olli Kallioniemi, MD, PhD, Tero Aittokallio, PhD, Krister Wennerberg, PhD, Caroline A Heckman, PhD

Blood (2013) 122 (21): 1668.

https://doi.org/10.1182/blood.V122.21.1668.1668

Published: 2013

Journal Articles

Primary T-Prolymphocytic Leukemia (T-PLL) Cells Are Sensitive To BCL-2 and HDAC Inhibitors: Results From High-Throughput Ex Vivo Drug Testing

Emma I Andersson, MSc, Tea Pemovska, MSc, Samuli Eldfors, MSc, Anneli Lauhio, MD, Paavo Pietarinen, MSc, Edgar Faber, MD, PhD, Olli Kallioniemi, MD, PhD, Krister Wennerberg, PhD, Caroline Heckman, PhD, Kimmo Porkka, MD, PhD, Satu Mustjoki, MD, PhD

Blood (2013) 122 (21): 3828.

https://doi.org/10.1182/blood.V122.21.3828.3828

Published: 2013

Journal Articles

Characterization Of a Novel In Vitro Circulation System Designed To Model The Migration Of Primary CLL Cells Across The Vascular Endothelium

Elisabeth J Walsby, Andrea GS Buggins, Ph.D., Stephen Devereux, FRCP, FRCPath, PhD, Paul Brennan, Chris Fegan, Chris Pepper

Blood (2013) 122 (21): 667.

https://doi.org/10.1182/blood.V122.21.667.667

Published: 2013

Journal Articles

A 3 Dimensional in Vitro Model to Test HL-60 Cell Line Sensitivity to Chemotherapy

Omar S. Aljitawi, MD, Dandan Li, Da Zhang, MD, Jonathan Mahnken, PhD, Suman Kambhampati, MD, Peter Van Veldhuizen, MD, Rama Garimella, PhD

Blood (2011) 118 (21): 4882.

https://doi.org/10.1182/blood.V118.21.4882.4882

Published: 2011

Journal Articles

Mouse Models of Myeloproliferative Neoplasms and Their Use In Preclinical Drug Testing

Richard A. Van Etten, MD, PhD

Blood (2010) 116 (21): SCI-35.

https://doi.org/10.1182/blood.V116.21.SCI-35.SCI-35

Published: 2010

NARROW

BCR-ABL1 p190 in CML: A Minor Breakpoint with a Major Impact

The Role of the BMP Pathway in Sustaining CML Stem Cells in the Bone Marrow Niche

High-Throughput Functional Ex-Vivo Drug Testing and Multi-Omics Profiling in Patients with Acute Myeloid Leukemia

The Influence of the Bone Marrow Niche on Drug Response Phenotypes of Blood Cancers

Gene-Drug Interactions in AML Patients Identified By RNA Sequencing and Comprehensive Ex Vivo Drug Sensitivity and Resistance Testing

Sequential Cellular Niche Plays a Crucial Role in the Generation of Enucleated Erythrocytes from Human Pluripotent Stem Cells

Single-Cell Drug Profiling Reveals Maturation Stage-Dependent Drug Responses in AML

Integration of Functional Ex Vivo Drug Testing and Molecular Profiling Reveals Novel Vulnerabilities in CMML

Identification of Optimized Compound Combinations for the Treatment of NUP98-NSD1+ AML

Ex-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma

Development of in Vivo Models of Paediatric Burkitt Lymphoma Allowing Therapeutic Target Analysis and Drug Testing

Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing

Stromal Cell Supported High-Throughput Drug Testing Of Primary Leukemia Cells For Comprehensive Assessment Of Sensitivity To Novel Therapies

Primary T-Prolymphocytic Leukemia (T-PLL) Cells Are Sensitive To BCL-2 and HDAC Inhibitors: Results From High-Throughput Ex Vivo Drug Testing

Characterization Of a Novel In Vitro Circulation System Designed To Model The Migration Of Primary CLL Cells Across The Vascular Endothelium

A 3 Dimensional in Vitro Model to Test HL-60 Cell Line Sensitivity to Chemotherapy

Mouse Models of Myeloproliferative Neoplasms and Their Use In Preclinical Drug Testing

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only